Cargando…
A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
BACKGROUND: Low dose naltrexone (LDN) is used off-label by many individuals with fibromyalgia to help manage their pain. There is no current systematic literature review summarising the evidence to support this use of LDN. The objectives of this study were to evaluate if patients with fibromyalgia p...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189400/ https://www.ncbi.nlm.nih.gov/pubmed/37206027 http://dx.doi.org/10.1016/j.heliyon.2023.e15638 |
_version_ | 1785043078564806656 |
---|---|
author | Partridge, Sarah Quadt, Lisa Bolton, Monica Eccles, Jessica Thompson, Charlie Colasanti, Alessandro Bremner, Stephen Jones, Christopher Iain Bruun, Karin Due Van Marwijk, Harm |
author_facet | Partridge, Sarah Quadt, Lisa Bolton, Monica Eccles, Jessica Thompson, Charlie Colasanti, Alessandro Bremner, Stephen Jones, Christopher Iain Bruun, Karin Due Van Marwijk, Harm |
author_sort | Partridge, Sarah |
collection | PubMed |
description | BACKGROUND: Low dose naltrexone (LDN) is used off-label by many individuals with fibromyalgia to help manage their pain. There is no current systematic literature review summarising the evidence to support this use of LDN. The objectives of this study were to evaluate if patients with fibromyalgia prescribed LDN have reduced pain scores and greater quality of life compared with those allocated to placebo in randomized controlled trials. Secondly to determine if changes in inflammatory markers and brain structure and function are observed among patients with fibromyalgia taking LDN. METHODS: Systematic literature searches were conducted in MEDLINE, Embase Classic + Embase, APA PsychInfo, and The Cochrane Library from inception to May 2022. Reference lists from the selected papers were cross-checked with database search results. RESULTS: Three studies met our inclusion criteria for the assessment of efficacy, and two studies on potential LDN mechanisms. Results indicated some evidence to suggest LDN reduces pain and increases quality of life. One study reported baseline erythrocyte sedimentation rate (ESR) predicted LDN response (≥30% reduction in fibromyalgia symptoms) and a second study showed plasma concentrations of inflammatory biomarkers were lower after LDN treatment. To our knowledge, there are no brain imaging studies reporting the effect of LDN in patients with fibromyalgia. All studies were based on small sample sizes, were restricted to women and the risk of bias was assessed to be high. There is also some evidence of publication bias. CONCLUSION: The strength of evidence from randomized controlled trials to support the use of LDN among patients with fibromyalgia is low. Two small studies suggest ESR and cytokines may be involved in the mechanism by which LDN exerts its effects. Two trials (INNOVA and FINAL) are currently in progress, but further work is needed among men and different ethnic groups. |
format | Online Article Text |
id | pubmed-10189400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-101894002023-05-18 A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia Partridge, Sarah Quadt, Lisa Bolton, Monica Eccles, Jessica Thompson, Charlie Colasanti, Alessandro Bremner, Stephen Jones, Christopher Iain Bruun, Karin Due Van Marwijk, Harm Heliyon Review Article BACKGROUND: Low dose naltrexone (LDN) is used off-label by many individuals with fibromyalgia to help manage their pain. There is no current systematic literature review summarising the evidence to support this use of LDN. The objectives of this study were to evaluate if patients with fibromyalgia prescribed LDN have reduced pain scores and greater quality of life compared with those allocated to placebo in randomized controlled trials. Secondly to determine if changes in inflammatory markers and brain structure and function are observed among patients with fibromyalgia taking LDN. METHODS: Systematic literature searches were conducted in MEDLINE, Embase Classic + Embase, APA PsychInfo, and The Cochrane Library from inception to May 2022. Reference lists from the selected papers were cross-checked with database search results. RESULTS: Three studies met our inclusion criteria for the assessment of efficacy, and two studies on potential LDN mechanisms. Results indicated some evidence to suggest LDN reduces pain and increases quality of life. One study reported baseline erythrocyte sedimentation rate (ESR) predicted LDN response (≥30% reduction in fibromyalgia symptoms) and a second study showed plasma concentrations of inflammatory biomarkers were lower after LDN treatment. To our knowledge, there are no brain imaging studies reporting the effect of LDN in patients with fibromyalgia. All studies were based on small sample sizes, were restricted to women and the risk of bias was assessed to be high. There is also some evidence of publication bias. CONCLUSION: The strength of evidence from randomized controlled trials to support the use of LDN among patients with fibromyalgia is low. Two small studies suggest ESR and cytokines may be involved in the mechanism by which LDN exerts its effects. Two trials (INNOVA and FINAL) are currently in progress, but further work is needed among men and different ethnic groups. Elsevier 2023-04-19 /pmc/articles/PMC10189400/ /pubmed/37206027 http://dx.doi.org/10.1016/j.heliyon.2023.e15638 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Article Partridge, Sarah Quadt, Lisa Bolton, Monica Eccles, Jessica Thompson, Charlie Colasanti, Alessandro Bremner, Stephen Jones, Christopher Iain Bruun, Karin Due Van Marwijk, Harm A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia |
title | A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia |
title_full | A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia |
title_fullStr | A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia |
title_full_unstemmed | A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia |
title_short | A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia |
title_sort | systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189400/ https://www.ncbi.nlm.nih.gov/pubmed/37206027 http://dx.doi.org/10.1016/j.heliyon.2023.e15638 |
work_keys_str_mv | AT partridgesarah asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT quadtlisa asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT boltonmonica asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT ecclesjessica asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT thompsoncharlie asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT colasantialessandro asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT bremnerstephen asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT joneschristopheriain asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT bruunkarindue asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT vanmarwijkharm asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT partridgesarah systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT quadtlisa systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT boltonmonica systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT ecclesjessica systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT thompsoncharlie systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT colasantialessandro systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT bremnerstephen systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT joneschristopheriain systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT bruunkarindue systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia AT vanmarwijkharm systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia |